Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis.
Thi Thuy NguyenNguyen Thanh NhuChia-Ling ChenChiou-Feng LinPublished in: Cancer medicine (2023)
Our meta-analysis demonstrated that the CD22/CD19 dual-targeting CAR-T-cell strategy has high efficiency with tolerable adverse effects in B-cell malignancies.